top of page

Abstract Lines

Our Pipeline

Targeting fundemental biology for radical therapeutic benifits

Abstract Lines

Indication

Discovery

Preclinical

Phase I

Phase II

CB-18

Peptide mitophagy

activator

CB-1902

Small molecule

mitophagy activator

CB-1025

Acidifying

nanoparticles

Penetrating Keratoplasty

Macular degeneration

Muscular
Dystrophy

Neuro-
Degeneration

Liver
Disease

Lysosomal
Diseases

Abstract Futuristic Background

Pipeline Fueled by Our MitoForm Platform

Unparalleled Scientific & Business Leadership

bottom of page